Alimentary Tract| Volume 48, ISSUE 6, P592-600, June 2016

Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study

Published:February 26, 2016DOI:



      Treatment of ulcerative colitis (UC) is aimed at maintaining corticosteroid-free remission and improving quality of life (QoL).


      Assess patients’ perception of disease burden and unmet clinical needs in moderate/severe UC patients.


      Adults surgery-free conventionally treated patients with Mayo score ≥6 were enrolled in an observational, cross-sectional, retrospective study in 11 European countries. Disease control was defined as Mayo score ≤2 with no sub-score >1. No corticosteroid was used the previous two months. Unmet clinical needs were defined as: non-controlled disease, self-perception of ‘moderate’/‘severe’ disease, and dissatisfaction with treatments. Disease burden on QoL and work productivity were assessed (EuroQol-5D-5L, Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and Work Productivity and Activity Impairment (WPAI) in UC questionnaire).


      UC patients (n = 253) with mean Mayo score at enrolment of 4.9, 44.3% of patients had Mayo score ≥6. Main treatment was 5-ASA (75%). Overall, 25% met the composite endpoint for unmet clinical needs.
      Mean (SD) questionnaire scores were: EQ-5D-5L-VAS, 71 (19.1), EQ-5D-5L utility, 0.77 (0.19), SIBDQ, 4.8 (1.3), and WPAI, 26% (32%).


      Patients with moderate/severe UC in the last 12 months treated with conventional therapies felt that their disease was not controlled and 25% reported unmet clinical needs. QoL and work productivity were seriously impaired.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cima R.R.
        • Pemberton J.H.
        Medical and surgical management of chronic ulcerative colitis.
        Archives of Surgery. 2005; 140: 300-310
        • Neuman M.G.
        Immune dysfunction in inflammatory bowel disease.
        Translational Research. 2007; 149: 173-186
        • Molodecky N.A.
        • Soon I.S.
        • Rabi D.M.
        • et al.
        Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.
        Gastroenterology. 2012; 142 (46–54.e42; quiz e30)
        • Marchioni Beery R.
        • Kane S.
        Current approaches to the management of new-onset ulcerative colitis.
        Clinical and Experimental Gastroenterology. 2014; 7: 111-132
        • Cohen R.
        • Skup M.
        • Ozbay A.B.
        • et al.
        Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
        Journal of Medical Economics. 2015; 18: 447-456
        • Ochsenkühn T.
        • D’Haens G.
        Current misunderstandings in the management of ulcerative colitis.
        Gut. 2011; 60: 1294-1299
        • Casellas F.
        • López-Vivancos J.
        • Badia X.
        • et al.
        Influence of inflammatory bowel disease on different dimensions of quality of life.
        European Journal of Gastroenterology and Hepatology. 2001; 13: 567-572
        • Cohen R.D.
        • Yu A.P.
        • Wu E.Q.
        • et al.
        Systematic review: the costs of ulcerative colitis in Western countries.
        Alimentary Pharmacology and Therapeutics. 2010; 31: 693-707
        • ECCO
        European Crohn's and Colitis Organization Guidelines: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis.
        2012 ([accessed 02.09.15])
        • Han S.W.
        • Gregory W.
        • Nylander D.
        • et al.
        The SIBDQ: further validation in ulcerative colitis patients.
        American Journal of Gastroenterology. 2000; 95: 145-151
        • Bokemeyer B.
        • Hardt J.
        • Hüppe D.
        • et al.
        Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
        Journal of Crohn's and Colitis. 2013; 7: 355-368
        • Sandborn W.J.
        • Hanauer S.
        • Van Assche G.
        • et al.
        Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases.
        Journal of Crohn's and Colitis. 2014; 8: 927-935
        • Bewtra M.
        • Brensinger C.M.
        • Tomov V.T.
        • et al.
        An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index.
        Inflammatory Bowel Diseases. 2014; 20: 1070-1078
        • Herdman M.
        • Gudex C.
        • Lloyd A.
        • et al.
        Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
        Quality of Life Research. 2011; 20: 1727-1736
      1. Euroqol publications. (accessed 2 September 2015).

        • Atkinson M.J.
        • Sinha A.
        • Hass S.L.
        • et al.
        Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.
        Health and Quality of Life Outcomes. 2004; 2: 12
        • Reilly M.C.
        • Zbrozek A.S.
        • Dukes E.M.
        The validity and reproducibility of a work productivity and activity impairment instrument.
        PharmacoEconomics. 1993; 4: 353-365
        • Blonski W.
        • Buchner A.M.
        • Lichtenstein G.R.
        Treatment of ulcerative colitis.
        Current Opinion in Gastroenterology. 2014; 30: 84-96
        • Frøslie K.F.
        • Jahnsen J.
        • Moum B.A.
        • et al.
        Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
        Gastroenterology. 2007; 133: 412-422
        • Solberg I.C.
        • Lygren I.
        • Jahnsen J.
        • et al.
        Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study).
        Scandinavian Journal of Gastroenterology. 2009; 44: 431-440
        • Levin B.
        • Lennard-Jones J.
        • Riddell R.H.
        • et al.
        Surveillance of patients with chronic ulcerative colitis. WHO Collaborating Centre for the Prevention of Colorectal Cancer.
        Bulletin of the World Health Organization. 1991; 69: 121-126
        • Schreiber S.
        • Panés J.
        • Louis E.
        • et al.
        Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey.
        BMC Gastroenterology. 2012; 12: 108
        • Hendrickson B.A.
        • Gokhale R.
        • Cho J.H.
        Clinical aspects and pathophysiology of inflammatory bowel disease.
        Clinical Microbiology Reviews. 2002; 15: 79-94
        • Burisch J.
        • Weimers P.
        • Pedersen N.
        • et al.
        Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease – an ECCO-EpiCom study.
        Journal of Crohn's and Colitis. 2014; 8: 1030-1042
        • Sandborn W.J.
        • Feagan B.G.
        • Marano C.
        • et al.
        Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
        Gastroenterology. 2014; 146 (96–109.e1)
        • Theede K.
        • Dahlerup J.F.
        • Fallingborg J.
        • et al.
        Biologic therapy in inflammatory bowel disease.
        Danish Medical Journal. 2013; 60: B4652
        • Sandborn W.J.
        • Feagan B.G.
        • Marano C.
        • et al.
        Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
        Gastroenterology. 2014; 146: 85-95
        • Shah E.
        • Rezaie A.
        • Riddle M.
        • et al.
        Psychological disorders in gastrointestinal disease: epiphenomenon, cause or consequence?.
        Annals of Gastroenterology. 2014; 27: 224-230
        • Sajadinejad M.S.
        • Molavi H.
        • Asgari K.
        • et al.
        Personality dimensions and type D personality in female patients with ulcerative colitis.
        International Journal of Research in Medical Sciences. 2012; 17: 898-904
        • Boye B.
        • Jahnsen J.
        • Mokleby K.
        • et al.
        The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease?.
        Inflammatory Bowel Diseases. 2008; 14: 680-686
        • Reinisch W.
        • Sandborn W.J.
        • Bala M.
        • et al.
        Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.
        Inflammatory Bowel Diseases. 2007; 13: 1135-1140
        • Hjortswang H.
        • Järnerot G.
        • Curman B.
        • et al.
        The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis.
        European Journal of Gastroenterology and Hepatology. 2003; 15: 1011-1020
        • Gibson P.R.
        • Vaizey C.
        • Black C.M.
        • et al.
        Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.
        Journal of Crohn's and Colitis. 2014; 8: 598-606
        • Hoivik M.L.
        • Moum B.
        • Solberg I.C.
        • et al.
        Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study.
        Inflammatory Bowel Diseases. 2012; 18: 1540-1549
        • Colombel J.
        • Reinisch W.
        • Gibson P.R.
        • et al.
        Clinical outcomes in continuous clinical responders with moderately to severely active ulcerative colitis: sub-analyses from the Pursuit-SC maintenance study.
        • Williet N.
        • Sandborn W.J.
        • Peyrin-Biroulet L.
        Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.
        Clinical Gastroenterology and Hepatology. 2014; 12 (1246–1256.e6)
        • Gray J.R.
        • Leung E.
        • Scales J.
        Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy.
        Alimentary Pharmacology and Therapeutics. 2009; 29: 1114-1120
        • Kemp K.
        • Griffiths J.
        • Campbell S.
        • et al.
        An exploration of the follow-up up needs of patients with inflammatory bowel disease.
        Journal of Crohn's and Colitis. 2013; 7: e386-e395
        • Rubin D.T.
        • Siegel C.A.
        • Kane S.V.
        • et al.
        Impact of ulcerative colitis from patients’ and physicians’ perspectives: results from the UC: NORMAL survey.
        Inflammatory Bowel Diseases. 2009; 15: 581-588
        • Goodhand J.R.
        • Wahed M.
        • Mawdsley J.E.
        • et al.
        Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.
        Inflammatory Bowel Diseases. 2012; 18: 2301-2309